On June 27, 2016, The New York Times reported that New York University medical school “quietly shut down eight studies at its prominent psychiatric research center” and dismissed Dr. Alexander Neumeister, the studies’ lead investigator was the director of the Molecular Imaging . . . Continue reading →
On Friday, April 6, the FDA approved another of Eli Lilly’s "breakthroughs" whose clinical value is questionable (at best). Continue reading →
"The problem of prescription overdose in the military has its parallel in civilian life. The tragic overdose victims in both spheres represent canaries in the coal mine–only the most obvious victims of what has become our national orgy of over using psychotropic drugs." Allen Frances MD Continue reading →
If mentally incapacitated troops are being drugged with dangerous, mind-altering drugs and deployed to battle against their will, how can we say that we have a volunteer army?
"Our systems of mental health care have become too medication focused, and it’s time for a broader approach. History will show that this national shift began this weekend in Portland, Oregon.” Continue reading →
"The risk was greater for individuals prescribed atypical rather than conventional drugs."
Antipsychotic Drugs and Risk of Venous Thromboembolism: Nested Case-Control Study BMJ
According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics (neuroleptics) are a controversial class of drugs: Risperdal (approved in 1993), Zyprexa (1994), Seroquel . . . Continue reading →
In the first half of the twenty-first century, U.S. psychiatrists are prescribing the second generation neuroleptics—Zyprexa, Risperdal, Geodon, Seroquel, Abilfy—to coerce innocent children and the elderly into submission.
Continue reading →
At the July 30, 2009 FDA advisory committee hearing, the only formal presentations at the meeting were a summary of the safety and efficacy data by the sponsor. Continue reading →